A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy

Stem Cells

Volumn 28, Issue 4, 2010, Pages 832-841

  Hingtgen, Shawn D ^a   Kasmieh, Randa ^a   Van De Water, Jeroen ^a   Weissleder, Ralph ^a   Shah, Khalid ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Pharmacokinetics; Stem cells cancer imaging; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; GPLUC L1 S TRAIL FUSION PROTEIN; GPLUC L2 S TRAIL FUSION PROTEIN; GPLUC S TRAIL FUSION PROTEIN; HYBRID PROTEIN; LUCIFERASE; S GPLUC L2 S TRAIL FUSION PROTEIN; S RLUCO L2 S TRAIL FUSION PROTEIN; S TRAIL FLUC FUSION PROTEIN; S TRAIL GPLUC FUSION PROTEIN; S TRAIL RLUC FUSION PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CANCER REGRESSION; CELL SURVIVAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MONITORING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; STEM CELL TRANSPLANTATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE; COCULTURE TECHNIQUES; GENE THERAPY; GENES, REPORTER; GLIOBLASTOMA; HUMANS; MICE; STEM CELL TRANSPLANTATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950978854     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.313     Document Type: Article

References (31)

1. Corsten MF, Shah K. Therapeutic stem-cells for cancer treatment: Hopes and hurdles in tactical warfare. Lancet Oncology 2008;9:376-384. (Pubitemid 351411654)
2. Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell 2008;132:544-548.
3. Sasportas LS, Kasmieh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 2009;106:4822-4827.
4. Corsten MF, Miranda R, Kasmieh R et al. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Research 2007;67:8994-9000. (Pubitemid 47535880)
5. Yip S, Sabetrasekh R, Sidman RL et al. Neural stem cells as novel cancer therapeutic vehicles. Eur J Cancer 2006;42:1298-1308. (Pubitemid 44208865)
6. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008;15:739-752. (Pubitemid 351627357)
7. Menon LG, Kelly K, Yang HW et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009;27:2320-2330.
8. Shah K, Bureau E, Kim DE et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 2005;57:34-41. (Pubitemid 40053313)
9. Shah K, Hingtgen S, Kasmieh R et al. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci 2008;28:4406-4413.
10. Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: Insights into atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1017-1024.
11. Koschny R, Walczak H, Ganten TM. The promise of TRAIL - Potential and risks of a novel anticancer therapy. J Mol Med 2007;85:923-935. (Pubitemid 47282789)
12. Shah K, Tang Y, Breakefield X et al. Real-time imaging of TRAILinduced apoptosis of glioma tumors in vivo. Oncogene 2003;22:6865-6872. (Pubitemid 37386686)
13. Shah K, Tung CH, Breakefield XO et al. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol Ther 2005;11:926-931.
14. Kelley SK, Harris LA, Xie D et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-38. (Pubitemid 32905115)
15. Griffith TS, Anderson RD, Davidson BL et al. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886-2894.
16. Shah K, Hsich G, Breakefield XO. Neural precursor cells and their role in neuro-oncology. Dev Neurosci 2004;26:118-130. (Pubitemid 40867970)
17. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 1996;175:1-13. (Pubitemid 26150042)
18. Kock N, Kasmieh R, Weissleder R et al. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007;9:435-442. (Pubitemid 46799987)
19. Arwert E, Hingtgen S, Figueiredo JL et al. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res 2007;67:7335-7342. (Pubitemid 47206563)
20. Hingtgen S, Ren X, Terwilliger E et al. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther 2008;7:3575-3585.
21. Shah K, Tung C, Yang K et al. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Research 2004;64:3236-3242. (Pubitemid 38581428)
22. Jaganathan J, Petit JH, Lazio BE et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines. Neurosurg Focus 2002;13:ecp1.
23. Venisnik K, Olafsen T, Gambhir S et al. Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Mol Imaging Biol 2007;9:267-277. (Pubitemid 47304776)
24. Wiley SR, Schooley K, Smolak PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682. (Pubitemid 26091143)
25. Shen J, Wu Y, Shi L et al. Construction and characterization of two versions of bifunctional EGFP-sTRAIL fusion proteins. Appl Microbiol Biotechnol 2007;76:141-149. (Pubitemid 47194667)
26. Bremer E, Samplonius D, Kroesen BJ et al. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 2004;6:636-645. (Pubitemid 39411100)
27. Venisnik KM, Olafsen T, Loening AM et al. Bifunctional antibody- Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Eng Des Sel 2006;19:453-460. (Pubitemid 44408905)
28. Ray P, Wu AM, Gambhir SS. Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res 2003;63:1160-1165. (Pubitemid 36348688)
29. Lin JH. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 1998;26:1202-1212.
30. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-3630.
31. Singec I, Jandial R, Crain A et al. The leading edge of stem cell therapeutics. Annu Rev Med 2007;58:313-328. (Pubitemid 46706517)